Outcomes of early cannulation arteriovenous graft versus PTFE arteriovenous graft in hemodialysis patients: A meta-analysis and systematic review

Arteriovenous graft (AVG) is an alternative for hemodialysis (HD) patients with end-stage renal disease when their permanent vascular accesses fail. Since the last decades, the most widely used materials in these patients have been polytetrafluoroethylene (PTFE)-AVGs. Recently, several studies have reported that early cannulation (EC)-AVG can be an alternative to PTFE-AVG. This systematic review and meta-analysis aimed to compare the outcomes of EC-AVG and PTFE-AVG in HD patients. We searched the Ovid Embase, Ovid MEDLINE, and Cochrane Central Register of Controlled Trials for the relevant studies published from 01.01.2000 to 19.12.2022 by keywords and free words. All randomized controlled trials (RCTs) and observational cohort studies comparing EC-AVG with PTFE-AVG were included. Ten studies were included in analysis: one RCT, six retrospective cohort studies, and three prospective cohort studies. The results showed shorter cannulation intervals (four studies, 1116 participants: mean difference −23.62 days, 95% CI [−32.03, −15.21], p < 0.05) and less central venous catheter (CVC) usage (four studies, 733 participants: OR 0.20, 95% CI [0.04, 0.92], p < 0.05) for EC-AVG compared with PTFE-AVG, while comparable outcomes of primary patency (eight studies, 1712 participants: HR 0.89, 95% CI [0.70, 1.12]), primary assisted patency (five studies, 1355 participants: HR 1.13, 95% CI [0.70, 1.84]), secondary patency (nine studies, 1920 participants: HR 0.93, 95% CI [0.66, 1.31]), and infection risk (four studies, 640 participants: HR 1.12, 95% CI [0.48, 2.58]). When compared to PTFE-AVG in HD patients, EC-AVG seems to exhibit shorter cannulation intervals, less CVC usage, and comparable outcomes of graft patency, and infection risk.